Endogenous sex hormones and prostate cancer: A quantitative review of prospective studies

British Journal of Cancer

Volumn 80, Issue 7, 1999, Pages 930-934

  Eaton, N E ^a   Reeves, G K ^a   Appleby, P N ^a   Key, T J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Androstanediol glucuronide; Prospective studies; Prostate cancer; Review; Steroid hormones

Indexed keywords

ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; ESTRADIOL; ESTROGEN; ESTRONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 0032950183     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690445     Document Type: Article

References (25)

1. Adlerereutz H (1990) Western diet and western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 50: 3-23
2. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT and Wingard DI. (1990) A prospective, population-based study of androstenedione, estrogens and prostatic cancer. Cancer Res 50: 169-173
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee Y, Lundberg S, Sparke B, Sternby NH and Tulinius H (1977) Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 20: 680-688
4. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W and Walsh PC (1995) Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27: 25-31
5. Comstock GW, Gordon GB and Hsing AW (1993) The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomark Prev 2: 219-221
6. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK and Reichardt JKV (1997) Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups:implications for prostate cancer risk. Prostate 33: 9-12
7. Dorgan JF, Alhanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J and Taylor PR (1998) Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomark Prev 7: 1069-1074
8. Flanders WD (1986) Case-control studies of selected hormones and prostate cancer: an epidemiological review. Alabama J Med Sci 23: 439-443
9. Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126
10. Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Vogelman JH, Imperato-McGinley J, Lobo RA and Orentreich N (1997) 5α-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomark Prev 6: 21-24
11. Henderson BE, Bernstein L, Ross RK. Depue RH and Judd HL (1988) The early in utero estrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57: 216-218
12. Hsing AW and Comstock GW (1993) Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomark Prev 2: 27-32
13. Montie JE and Pienla KJ (1994) Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 43: 892-899
14. Nomura AMY, Heilbrun LK, Stemmermann GN and Judd HJ (1988) Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48: 3515-3517
15. Nomura AMY and Kolonel LN (1991) Prostate cancer: a current perspective. Am J Epidemiol 13: 200-207
16. Nomura AMY, Stemmermann GN, Chyou PH, Henderson BE and Stanczyk FZ (1996) Serum androgens and prostate cancer. Cancer Epidemiol Biomark Prev 5: 621-625
17. Parker SL, Tong T, Boldon S and Wingo PA (1996) Cancer statistics, 1996. Cancer J Clin 46: 5-27
18. Parkin DM, Muir CS, Whelan SL, Gao Y, Ferlay J and Powell J (1992) Cancer Incidence in Five Continents, Vol VI. IARC Scientific Publication No. 129. International Agency for Research on Cancer: Lyon, France
19. Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC and Ross RK (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55: 3973-3975
20. Ross RK, Bernstein L, Judd H, Hanisch R, Pike MC and Henderson BE (1986) Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76: 45-48
21. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC and Henderson BE (1992) 5α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887-897
22. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE and Mack TM (1991) Cancers of the breast and prostate among Japanese and white immigrants to Los Angeles County. Br J Cancer 63: 963-966
23. Thomas HV, Reeves GK and Key TJA (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 8: 922-928
24. Valten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S and Jellum E (1997) Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomark Prev 6: 967-969
25. Vermeulen A and Verdonck G (1992) Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 74: 939-942